Journal of the National Cancer Institute

Men faced high fracture risk after prostate cancer drugs

Three-year fracture risk exceeded 25% without a recent fracture and 50% with one; it remained above 44% among men with prior fractures using bone-health medicines.

Our read

Populations
Studied:
Cohort study of 10,463 men with advanced prostate cancer
What changed:
Three-year fracture risk exceeded 25% in men without prior fracture and 50% in those with a prior fracture
The catch:
Findings concern Medicare-insured men with advanced prostate cancer, not earlier-stage disease
Stake:
At least one author takes fees from Pfizer, which develops enzalutamide.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

An observational study examined records for 10,463 Medicare-insured men with advanced prostate cancer. They received abiraterone acetate with prednisone or enzalutamide between 2013 and 2020. Researchers identified fractures from insurance claims, with follow-up through December 2020.

Three-year fracture risk exceeded 25% among men without a fracture in the year before starting these drugs. Among 1,445 men with a fracture that year, it exceeded 50% and remained above 44% among those using bone-health medicines. A recent fracture was associated with a 2.84-fold fracture risk. Bone-health medicine use was associated with a 23% lower relative fracture risk. The authors said the findings suggested limited benefit from these medicines in patients with poor bone quality.

Why it matters

For older men receiving advanced prostate cancer care, the findings bear on how best to address fracture risk. The authors called for early identification and intervention for patients at high risk.

Caveats

This observational study could not establish whether the cancer drugs caused fractures or whether bone-health medicines prevented them. Its findings concern Medicare-insured men with advanced prostate cancer, not men with earlier-stage disease.

Comments

Be the first to comment.